- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 2,549
matching trials from the live ClinicalTrials.gov search.
- Conditions
- XXB750 in Healthy Participants
- Interventions
- XXB750, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Multiple Myeloma
- Interventions
- Melphalan, Panobinostat
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more
- Conditions
- H7N9 Influenza
- Interventions
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant, H7N9c high dose without adjuvant
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 6
- States / cities
- San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Trametinib, Ruxolitinib, Retifanlimab
- Drug
- Lead sponsor
- Peter Hosein, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- Zometa
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Solid Tumors, Excluding Breast Cancer
- Interventions
- dovitinib (TKI258), fluvoxamine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- The Bronx, New York • San Antonio, Texas
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Fanconi Anemia
- Interventions
- Eltrombopag
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 6 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- AEE788, everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Durham, North Carolina • Houston, Texas
- Conditions
- Arthritis, Gouty
- Interventions
- canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
- Biological · Drug · Other
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • New Brunswick, New Jersey
- Conditions
- Hypertension
- Interventions
- amlodipine/benazepril
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,422 participants
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis
- Interventions
- Imatinib Mesylate (Gleevec)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hidradenitis Suppurativa
- Interventions
- secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 29
- States / cities
- Rogers, Arkansas • San Diego, California • Whittier, California + 22 more
- Conditions
- Carcinoma, Basal Cell, Recurrent Skin Cancer, Skin Neoplasms, Basal Cell Nevus Syndrome
- Interventions
- Buparlisib, Sonidegib
- Drug
- Lead sponsor
- Anne Chang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 25
- States / cities
- Anniston, Alabama • Burbank, California • La Palma, California + 22 more
- Conditions
- Asthma
- Interventions
- Indacaterol maleate, Indacaterol acetate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Project EVO Multi- Treatment
- Device
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Warm Autoimmune Hemolytic Anemia (wAIHA)
- Interventions
- Ianalumab, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Farmington Hills, Michigan • Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Ribociclib, Placebo
- Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Augusta, Georgia • Beech Grove, Indiana + 8 more
- Conditions
- Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
- Interventions
- letrozole, lapatinib, everolimus
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland